These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 20142724

  • 1. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG.
    Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
    [Abstract] [Full Text] [Related]

  • 2. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
    Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA.
    J Clin Oncol; 2009 Aug 01; 27(22):3584-90. PubMed ID: 19487381
    [Abstract] [Full Text] [Related]

  • 3. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
    Rini BI, Stein M, Shannon P, Eddy S, Tyler A, Stephenson JJ, Catlett L, Huang B, Healey D, Gordon M.
    Cancer; 2011 Feb 15; 117(4):758-67. PubMed ID: 20922784
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
    Grünwald V, Desar IM, Haanen J, Fiedler W, Mouritzen U, Olsen MW, van Herpen CM.
    Acta Oncol; 2011 Jan 15; 50(1):121-6. PubMed ID: 21174612
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
    Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ.
    Cancer; 2012 Apr 01; 118(7):1868-76. PubMed ID: 21898375
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C, Imarisio I, Ganini C, Morbini P, Vercelli A, Bregant C, Porta C.
    Future Oncol; 2012 Dec 01; 8(12):1605-12. PubMed ID: 23231522
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
    Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM.
    Clin Genitourin Cancer; 2015 Jun 01; 13(3):218-24. PubMed ID: 25465491
    [Abstract] [Full Text] [Related]

  • 17. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
    Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ.
    J Clin Oncol; 2009 Mar 20; 27(9):1432-9. PubMed ID: 19224847
    [Abstract] [Full Text] [Related]

  • 18. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A.
    Eur Urol; 2011 Sep 20; 60(3):448-54. PubMed ID: 21612860
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ.
    J Clin Oncol; 2009 Sep 01; 27(25):4068-75. PubMed ID: 19652072
    [Abstract] [Full Text] [Related]

  • 20. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ, Tian J, Chen X, Wang D, Li CL.
    Clin Genitourin Cancer; 2017 Feb 01; 15(1):139-144. PubMed ID: 27338518
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.